Navigation Links
Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
Date:3/4/2008

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the Food and Drug Administration ("FDA") has cleared its 510(k) submission for its Plexur M(TM) Biocomposite. Adapting the Company's proprietary Plexur(R) Technology, Plexur M(TM) is intended for use in filling bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. During the healing process, Plexur M(TM) is remodeled and replaced by host bone.

Plexur M(TM) is a uniquely flexible biomaterial composed of mineralized cortical fibers bound in a resorbable polymer. When heated, this biocomposite becomes moldable and pliable allowing a surgeon numerous options for use during surgery. During the cooling process, Plexur M(TM) hardens providing a versatile porous scaffold to assist in regeneration of damaged and diseased bones. It is an ideal medium for placing screws with no cracking or resultant particulate shedding and can be reamed and reverse-reamed without dislodging the graft or damaging the surrounding bone. Plexur M(TM) uses proprietary processing steps that have been shown to inactivate viruses and is terminally sterilized.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased to be able to introduce the Plexur M(TM) Biocomposite. Our internal team has done an excellent job to develop this product and receive FDA clearance for orthopedic applications. We anticipate filing an additional 510(k) submission for the use of Plexur M(TM) in spinal applications in the first part of the second quarter. We plan to continue our research and development activitie
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
2. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech to Present at Sidoti Conference in San Francisco
5. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
6. Ventria Receives Friends of Education Award From Geary County School District
7. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
8. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
9. Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
10. Vermillion Receives NASDAQ Notice of Non-Compliance
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Morton Grove, IL (PRWEB) February 26, 2015 ... this month for the development of oncology drug substances. ... and start up of their new Potent Compound Suite ... organization operating a 36,000 square foot, cGMP facility in ... small molecule cGMP manufacturing of potent compounds up to ...
(Date:2/26/2015)... LOS ANGELES , Feb. 26, 2015 ... diversified life sciences company with interests in the natural ... platform technology, announced today that its products will be ... upcoming Roth Capital Partners, 27 th Annual Growth ... Ritz Carlton, located at 1 Ritz Carlton Drive, ...
(Date:2/26/2015)... --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... 35 th Annual Health Care Conference on Tuesday, March ... .  Lexicon management will provide an overview of Lexicon,s ... the presentation will be available through Lexicon,s website at ... available at www.lexpharma.com until April 3, 2015. ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 CytomX, ... of cancer, today announced that Sean McCarthy , ... overview at the upcoming Cowen and Company 35 th ... . Dr. McCarthy,s presentation will take place at ... About CytomX Therapeutics CytomX Therapeutics develops Probody™ therapeutics ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... ... of Energy (DOE) bio-energy research centers, has selected Surety’s AbsoluteProof trusted time-stamping service to ... ... the leading provider of data integrity protection solutions , today announced that the ...
... , WILMINGTON, Del. ... AZN ) and the University of Virginia (UVa) ... a strategic research collaboration to enhance development of new ... secondary focus on peripheral vascular disease (PAD). , (Logo: ...
... , , BRIARCLIFF MANOR, N.Y., Dec. ... of the International Society for Medical Publication Professionals (ISMPP) will ... UK. More than 100 attendees are expected at this prestigious ... medical writers and medical agencies to discuss the changing world ...
Cached Biology Technology:Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... 31, 2010) -- A new imaging system using six ... (ocular fundus) may pave the way for doctors to ... such as age-related macular degeneration and diabetic retinopathy. The ... Scientific Instruments, which is published by the American ...
... Barbara, Calif.) Two new groundbreaking scientific papers by ... nanosize biological particles with the potential to fight cancer ... are considered "green" nanobiotechnology because they use no artificial ... biochemistry at UCSB, explained that there is nothing short ...
... created the first two-terminal memory chips that use only ... planet, in a way that should be easily adaptable ... limits of miniaturization subject to Moore,s Law. ... James Tour showed how electrical current could repeatedly break ...
Cached Biology News:LEDs illuminate eye for ocular disease screening 2Developments in nanobiotechnology at UCSB point to medical applications 2Silicon oxide circuits break barrier 2Silicon oxide circuits break barrier 3Silicon oxide circuits break barrier 4
... imaging system allows imaging of fluorescent and ... 46cm at a pixel size as low ... suitable for protein electrophoresis in the proteomics ... Fuji s FLA-5100 includes four imaging solutions ...
... Biometras T1 Thermocycler provides high speed ... been optimized with a TGradient Thermocycler can ... thermocycler comes with a silver block for ... for 384 well plates or in-situ applications ...
... Sciclone inL10 Workstation from Caliper represents a ... for the first time the ability to ... react to changing conditions. In addition, ... viscosity due to changes in temperature, and ...
... disposable microfiltration devices for the fast and reliable ... l to 500 l. They can be used ... tubes. Product Features: High-flux Polyethersulphonemembrane ... hold up volume ( Fast and reproducible performance ...
Biology Products: